Insmed Inc (INSM) concluded trading on Thursday at a closing price of $68.96, with 3.61 million shares of worth about $248.83 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -4.59% during that period and on April 24, 2025 the price saw a loss of about -2.60%. Currently the company’s common shares owned by public are about 179.38M shares, out of which, 177.62M shares are available for trading.
Stock saw a price change of -1.77% in past 5 days and over the past one month there was a price change of -12.20%. Year-to-date (YTD), INSM shares are showing a performance of -0.12% which increased to 186.02% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $21.92 but also hit the highest price of $84.91 during that period. The average intraday trading volume for Insmed Inc shares is 1.93 million. The stock is currently trading -2.83% below its 20-day simple moving average (SMA20), while that difference is down -8.38% for SMA50 and it goes to -6.66% lower than SMA200.
Insmed Inc (NASDAQ: INSM) currently have 179.38M outstanding shares and institutions hold larger chunk of about 106.38% of that.
The stock has a current market capitalization of $12.54B and its 3Y-monthly beta is at 0.85. It has posted earnings per share of -$5.59 in the same period. It has Quick Ratio of 5.12 while making debt-to-equity ratio of 4.60. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for INSM, volatility over the week remained 4.59% while standing at 5.63% over the month.
Analysts are in expectations that Insmed Inc (INSM) stock would likely to be making an EPS of -1.36 in the current quarter, while forecast for next quarter EPS is -1.37 and it is -3.52 for next year. For the current quarter EPS, analysts have given the company a lowest target -1.5 which is -1.01 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -1.06 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 5.71% while it is estimated to increase by 28.85% in next year. EPS is likely to grow at an annualized rate of 50.65% for next 5-years, compared to annual growth of -13.12% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by RBC Capital Mkts on February 25, 2025 offering an Outperform rating for the stock and assigned a target price of $100 to it. Coverage by Truist stated Insmed Inc (INSM) stock as a Buy in their note to investors on April 23, 2024, suggesting a price target of $48 for the stock. On February 15, 2024, Wolfe Research Initiated their recommendations, while on December 08, 2023, Wells Fargo Initiated their ratings for the stock with a price target of $55. Stock get an Overweight rating from JP Morgan on November 20, 2023.
